Clinical Utility of Plasma-Based Comprehensive Molecular Profiling in Advanced Non-Small-Cell Lung Cancer.

Robert D Schouten Daan C L VessiesLinda J W BoschNicole P BarloAnne S R van LindertSaskia A G M CillessenDaan van den BroekMichel van den Heuvel Kim Monkhorst

Published in: JCO precision oncology (2021)

Plasma-CMP is a reliable tool in the primary diagnostic setting, although it cannot fully replace SoC-TMP. Complementary profiling by combined SoC-TMP and plasma-CMP increased the proportion of patients who are eligible for targeted treatment.

Keyphrases

advanced non small cell lung cancer
end stage renal disease
newly diagnosed
epidermal growth factor receptor
ejection fraction
single cell
prognostic factors
peritoneal dialysis
drug delivery
patient reported outcomes
cancer therapy
single molecule
combination therapy